Navidea Biopharmaceuticals, Inc (NAVB) Financials

NAVB Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2023 5.7 million 8.7 million
June 30, 2023 8.2 million 9.0 million
March 31, 2023 2.4 million 11.9 million
Dec. 31, 2022 4.4 million 12.5 million

NAVB Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -10.3 million 10347
June 30, 2023 4.6 million -33842
March 31, 2023 -1.8 million 19669
Dec. 31, 2022 -2.5 million 34895

NAVB Net Income

No data available :(

NAVB Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 3.9 million - 10696
June 30, 2023 6.1 million - 19564
March 31, 2023 33795 - 11298
Dec. 31, 2022 2.0 million - 20288

NAVB Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 99.4 million
June 30, 2023 48.2 million
March 31, 2023 32.7 million
Dec. 31, 2022 32.4 million

NAVB Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 16523 829613 1.3 million -
June 30, 2023 65337 1.1 million 1.3 million -
March 31, 2023 39409 1.3 million 1.2 million -
Dec. 31, 2022 72039 1.9 million 1.3 million -

NAVB Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 - -
June 30, 2023 - -
March 31, 2023 - -
Dec. 31, 2022 610 50036

NAVB

Price: $0

52 week price:
0.00
0.17

Earnings Per Share: -0.20 USD

P/E Ratio: -0.17

Exchange: PNK

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 89200

Market Capitalization: 3.5 million

Links: